MannKind outlines $110M-$120M 2026 Furoscix revenue target as ReadyFlow ships in weeks (NASDAQ:MNKD)
seekingalpha.com · 2026-08-06
MannKind (MNKD) Q2 2026 earnings call recap: Afrezza pediatrics uptake, Furoscix ReadyFlow launch timing, revenue mix, cash, and risks—read now.
Read the full story at seekingalpha.com →
Is MNKD undervalued? See TickrTrends' fair value analysis →